Connect with us

Research Reports

Constructive Digitization to drive the Non Infectious Macular Edema Treatment Market

The Personal Watercraft Market To Fathom The Depth Of Innovation

 

The Non Infectious Macular Edema Treatment Market is likely to mark stellar growth in the upcoming period. The current situation calls for conducive integrated healthcare models that do away with middlemen regarding offering various products and services. Drug manufacturers, hospital systems, PBMs (pharmacy benefit managers), wholesale distributors, hospital systems, medical insurers, and retail pharmacy outlets – are all into the integration of healthcare strategies. This would be how the healthcare vertical function in the upcoming period.

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular edema, which is a severe case of swelling in the retina possibly leading to blindness. Looking at the significant increase in the number of macular edema cases, many new drugs have been introduced in the global market and several are still in the pipeline. Anti-VEGF and corticosteroid therapies are considered to be the standard therapies for prevention of vision loss in patients in various indications of macular edema.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/22984

The other drug types that are part of the macular edema treatment market are immunosuppressant and biologics, and many new treatment types are expected to be introduced as the market continues to grow. The outcomes of a recent market research by Persistence Market Research has revealed the growth of the global non-infectious macular edema treatment market at a CAGR of 7.0% during the forecast period 2018-2026. The study also projects the market to reach a valuation of over US$ 17,200 Mn by the end of 2026.

Company Profiles:

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman – La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.
  • Others.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/22984

Increase in the Number of Combination Therapies to Boost Demand in the Global Market

Novel biological drugs are now being introduced owing to the increase in prevalence of macular edema cases. Even standard drugs such as Corticosteroids and anti-VEGF that are viewed as the first-line treatment for non-infectious macular edema are facing a limitation in use due to the associated side effects. This has given a leverage to companies to come up with other effective therapies. The new trends include a rise in the prescription of combination therapies that are more reliable in complex cases. This has increased the efficiency of the treatment process. An increase in the use of combination drugs is anticipated to spur demand in the non-infectious macular edema treatment market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/22984

Rate of Incidence of Macular Edema High in Europe Due to the Rising Prevalence of Diabetes

Diabetes related complications are one of the main causes of macular edema and there is a high rate of Diabetic Macular Edema (DME) in several countries across Europe. This makes the European market highly lucrative for manufacturers to introduce newer therapies and treatment options. However, the market forecast for the period of 2018-2026 projects North America to be the leading region in the global non-infectious macular edema treatment market with a valuation of over US$ 5,900 Mn by the end of 2026. In terms of growth rate, APAC is anticipated to exhibit growth at the fastest rate during the forecast period.

Related Reports:

Ineffective Esophageal Motility Treatment Market

Injectable Drug Delivery Market

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Continue Reading
Editorial & Advertiser disclosure

Recommended